A paclitaxel prodrug nanoparticles with glutathion/reactive oxygen species dual‐responsive and CD206 targeting to improve the anti‐tumour effect

As a first‐line anticancer drug, paclitaxel has shortcomings, such as poor solubility and lack of tumour cell selectivity, which limit its further applications in clinical practice. Therefore, the authors aimed to utilise the characteristics of prodrug and nanotechnology to prepare a reactive oxygen...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Changhai, Jiao, Yuwen, Zhang, Xinyu, Guo, Mingxue, Zhang, Qing, Hu, Wenjun, Dong, Shuang, Jakkree, Tangthianchaichana, Lu, Yang, Wang, Jinling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374550/
https://www.ncbi.nlm.nih.gov/pubmed/37055350
http://dx.doi.org/10.1049/nbt2.12119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374550/
https://www.ncbi.nlm.nih.gov/pubmed/37055350
http://dx.doi.org/10.1049/nbt2.12119

Ejemplares similares